Nephropathy Clinical Trial
Official title:
N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes
In patients undergoing coronary angiography, the incidence of contrast induced
nephropathy(CIN)varies widely and ranges from < 5% in the lowest risk patients, to nearly
50% in the highest risk patients. Prior data has shown oral n-acetyl cysteine (NAC) to be
effective in reducing the incidence of CIN.Due to extensive first pass metabolism, the
bioavailability of oral NAC is poor and ranges from 4%-10%. We hypothesize that the
incidence of CIN will be reduced in patients with ACS who undergo PCI by the prophylactic
administration of intravenous NAC.
This is a prospective, randomized, double-blind, placebo-controlled single center clinical
trial designed to evaluate the effects of intravenous NAC on patients with acute coronary
syndromes (ACS)undergoing coronary angiography and/or percutaneous coronary intervention
(PCI). The medication Acetadote is provided by Cumberland Pharmaceuticals Inc
(www.cumberlandpharma.com).
Patients will be excluded if they have end-stage renal disease requiring dialysis,known
hypersensitivity to NAC or a history of life-threatening contrast reaction. Primary
end-point is incidence of CIN. Secondary end-points are in-hospital mortality,30-day
mortality,duration of hospitalization and change in serum cystatin C level.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Recruiting |
NCT01448889 -
Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy
|
N/A | |
| Active, not recruiting |
NCT05026021 -
Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia
|
||
| Completed |
NCT02470247 -
Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy in High Risk Patients
|
N/A | |
| Recruiting |
NCT05511779 -
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
|
Phase 2 | |
| Active, not recruiting |
NCT03584217 -
Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03620773 -
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
|
Phase 1/Phase 2 | |
| Completed |
NCT03618420 -
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
|
Phase 1/Phase 2 | |
| Completed |
NCT02575092 -
The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05839314 -
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
|
Phase 4 | |
| Completed |
NCT01638663 -
Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)
|
Phase 2 | |
| Completed |
NCT01213498 -
The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy
|
Phase 2 | |
| Completed |
NCT01208701 -
The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy
|
Phase 2 | |
| Completed |
NCT01214746 -
The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man
|
Phase 2 | |
| Active, not recruiting |
NCT00655330 -
Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy
|
N/A | |
| Completed |
NCT00308347 -
A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)
|
Phase 3 | |
| Terminated |
NCT00579995 -
A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate
|
N/A | |
| Completed |
NCT05986474 -
Development of Synthetic Medical Data Generation Technology to Predict Postoperative Complications
|
||
| Recruiting |
NCT03886714 -
Screening for Fabry Disease in Renal Transplantation
|
||
| Recruiting |
NCT06325059 -
The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases
|
N/A |